Select Location
What is your delivery location?
We need your delivery location to continue browsing
Select Location
We need your delivery location to continue browsing
Prescription Required
cipla
30 tablet
Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate
Keep in cold place
Delivering To:
Overview
Viraday (Emtricitabine + Tenofovir disoproxil fumarate + Efavirenz) tablet is a combination of three antiretroviral medications. It is used for the treatment of HIV (human immunodeficiency virus) infection. This medication belongs to a class of medications known as nucleoside reverse transcriptase inhibitors (NRTIs). Viraday tablet boosts your immune system to fight against infection and helps to reduce the amount of HIV in your body, and improves the quality of life. It is important to take the Viraday tablet as prescribed by your doctor. Do not take this medicine in the wrong way, as it may lead to some serious side effects.
HIV
HIV infection
The following are the possible side effects that can occur during your treatment with Viraday tablet. Contact your medical practitioner immediately if any of the above-mentioned side effects appear.
Dizziness
Unusual sweating
Skin rash
Itching
Indigestion
Constipation
Redness of skin
Headache
Taste change
Blurred vision
Fever
Confusion
Chills
Nightmare
The following are the possible side effects that can occur during your treatment with Viraday tablet. Contact your medical practitioner immediately if any of the above-mentioned side effects appear.
Dizziness
Unusual sweating
Skin rash
Itching
Indigestion
Constipation
Redness of skin
Headache
Taste change
Blurred vision
Fever
Confusion
Chills
Nightmare
The following are the possible side effects that can occur during your treatment with Viraday tablet. Contact your medical practitioner immediately if any of the above-mentioned side effects appear.
Dizziness
Unusual sweating
Skin rash
Itching
Indigestion
Constipation
Redness of skin
Headache
Taste change
Blurred vision
Fever
Confusion
Chills
Nightmare
Alcohol
unsafe
Do not consume alcohol while taking Viraday tablet.
Pregnancy
consult your doctor
Do not take Viraday without consulting the doctor, in case of pregnancy.
Breast Feeding
consult your doctor
Do not take Viraday tablet if you're breastfeeding. Consultation of the doctor is advised.
Driving
danger
It is advisable not to drive or operate heavy machinery, you may feel dizzy as one of the side effects of Viraday.
Kidney
precaution
Do not take Viraday tablet without a doctor's consultation in case of kidney problems.
Liver
precaution
Share your medical history with the doctor in case of liver disease before taking Viraday tablet.
It is advisable not to miss a dose. If you miss a scheduled dose of Viraday tablets, contact your doctor immediately.
Viraday tablet is an antiviral medication that prevents the human immunodeficiency virus (HIV) from multiplying in your body. Viraday tablet also helps to delay the production of HIV infection and improve the quality of life.
Some common side effects are:- fatigue, headache, nausea, taste change, stomach ache, diarrhea, fever, chills, blurred vision, weight loss, abnormal dreams, etc.
This medication helps boost your immune system to fight against infection. It also helps to delay the production of HIV infection.
If you miss a scheduled dose of the Viraday tablet, contact your doctor immediately.
It is available in the strength of 200mg/300mg/600mg.
Before using this medication, speak with your doctor if you have a history of liver or renal illness, mental health issues, seizures, or pregnancy.
Make an immediate call to your local poison control center or emergency room if you suspect there was an overdose. signs of a severe medication reaction are Wheezing, tightness in the chest, fever, itching, a nasty cough, blue or gray skin, convulsions, or swelling of the face, lips, tongue, or neck are some of these symptoms.
At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.
Enjoy the convenience of fast home delivery, secure packaging, and affordable prices*—plus *special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.
Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.
We currently ship to:
Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!
Arribas, J. R., Pozniak, A. L., Gallant, J. E., Dejesus, E., Gazzard, B., Campo, R. E., et al. (2008). Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus zidovudine/lamivudine and efavirenz in antiretroviral‑naïve patients: virologic, immunologic, and morphologic changes—a 96‑week analysis. Journal of Acquired Immune. Deficiency Syndromes, 47(1), 74–81.
Author(s) unspecified. (2017). Efficacy and safety of a once‑daily single‑tablet regimen of tenofovir, lamivudine, and efavirenz assessed at 144 weeks among antiretroviral‑naïve and experienced HIV‑1‑infected Thai adults. Journal of Antiviral Therapy and Clinical Outcomes, 21(4), 220–229.
Author(s) unspecified. (2025). Efficacy and safety of tenofovir and lamivudine in combination with efavirenz in HIV/HBV co‑infected, treatment‑naïve individuals. Manuscript (ClinicalTrials.gov: NCT01751555).
Pujari, S., Sharma, V., Gupta, R., & Khan, M. (2024). Incidence and pattern of adverse drug reactions to first‑line antiretroviral therapy (tenofovir, lamivudine, and efavirenz): A prospective study in India. Indian Journal of Clinical Pharmacy, 15(2), 45–53.
